(Q37425654)

20 August 2017

1 reference

title

Endothelin receptor antagonists: status and learning 20 years on. (English)

1 reference

20 August 2017

Michael J Palmer

1

1 reference

20 August 2017

publication date

1 January 2009

1 reference

Progress in medicinal chemistry

20 August 2017

published in

1 reference

20 August 2017

volume

47

1 reference

20 August 2017

page(s)

203-237

1 reference

Characterization of a coronary vasoconstrictor produced by cultured endothelial cells

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

1 reference

7 January 2021

Contribution of endogenous generation of endothelin-1 to basal vascular tone

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

The endothelin system and its antagonism in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Alternatively spliced mRNAs for human endothelin-2 and their tissue distribution.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Cloning and expression of a cDNA encoding an endothelin receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Role of endothelin-1 in hypertension and vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Endothelin antagonism in pulmonary hypertension, heart failure, and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2'-amino-N- (3,4-dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1,

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Confocal fluorescence microscopy for high-throughput screening of G-protein coupled receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

The potential of endothelin antagonism as a therapeutic approach

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

The crystal structure of human endothelin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Conformation of endothelin in aqueous ethylene glycol determined by 1H-NMR and molecular dynamics simulations

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

The structure and specificity of endothelin receptors: their importance in physiology and medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Modeling and docking the endothelin G-protein-coupled receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Selective and mixed endothelin receptor antagonism in cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Bosentan therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Sitaxsentan therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Role of endothelin ETB receptor in the pathogenesis of monocrotaline-induced pulmonary hypertension in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ET(B) selectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Endothelin receptor antagonists in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Endothelin-receptor antagonists in arterial hypertension: further indications?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

A novel combination of opiates and endothelin antagonists to manage pain without any tolerance development

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Endothelin receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Structure-based maximal affinity model predicts small-molecule druggability.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

1 reference

7 January 2021

Lead- and drug-like compounds: the rule-of-five revolution

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

The influence of drug-like concepts on decision-making in medicinal chemistry

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Ligand efficiency: a useful metric for lead selection

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

The maximal affinity of ligands

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Fragment screening: an introduction

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

New non-peptide endothelin-A receptor antagonists: synthesis, biological properties, and structure-activity relationships of 5-(dimethylamino)-N-pyridyl-,-N-pyrimidinyl-,-N-pyridazinyl-, and -N-pyrazinyl-1-naphthalenesulfonamides

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Endothelin receptor antagonists: structures, synthesis, selectivity and therapeutic applications

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Clinical pharmacology of bosentan, a dual endothelin receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

1 reference

7 January 2021

Le bosentan dans le traitement des ulcères digitaux évolutifs au cours de la sclérodermie systémique (9 cas)

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Treatment of complications associated with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4).

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa stu

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Pharmacokinetics and pharmacodynamics of the ETA-selective endothelin receptor antagonist SPP301 in healthy human subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Synthesis and structure-activity relationships in a series of ethenesulfonamide derivatives, a novel class of endothelin receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4'-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ET(A) antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) sele

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Discovery and synthesis of (S)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2- (4,6-dimethylpyrimidin-2-yloxy)-3,3-diphenylpropionic acid (LU 302872), a novel orally active mixed ET(A)/ET(B) receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Ambrisentan, a non-peptide endothelin receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Inhibitors of endothelin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Single-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546).

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

The design and synthesis of a novel series of indole derived selective ET(A) antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

Endothelin receptor antagonist triterpenoid, myriceric acid A, isolated from Myrica cerifera, and structure activity relationships of its derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900205-1

7 January 2021

10.1016/S0079-6468(08)00205-1

Identifiers

DOI

1 reference

20 August 2017

1 reference